Phase 3 N=232 Maxigesic® IV Phase 3 Exposure Study
Postoperative Pain
Primary: Incidence of TEAEs (Treatment-emergent Adverse Events) — 256; 38 Treatment-Emergent Adverse Events
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=30 Microfidelity (MIFI) Ablation Technology Versus Standard Ablation Catheter for Atrioventricular Nodal Ablation
Atrial Fibrillation
Primary: The Time Differences Between the 2 Arms for Acute Success of Ablation Identified by a Junctional Rhythm or Complete Heart Block — 5; 4 seconds
Phase 4 N=118 Pain Control Following Sinus Surgery
Sinusitis · Opioid Use · Opioid Abuse
Primary: Pain Severity — 12.4; 8.5 units on a scale
Phase 3 N=1,012 Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis
Ulcerative Colitis
Primary: Percentage of Participants in Clinical Remission at 10 Weeks — 18.4; 6.0; 21.0 Percentage — p=0.0001
Phase 3 N=90 Clinical Trial Comparing Two Bladder Instillations for IC/BPS
Interstitial Cystitis · Bladder Pain Syndrome
Primary: Change From Baseline in Treatment Response as Measured by the Total Score on the O'Leary-Sant Questionnaire — -6.7; -5.8 scores on a scale
Phase 1 N=88 Clearance of 25-hydroxyvitamin D in Chronic Kidney Disease
Chronic Kidney Disease
Primary: Metabolic Clearance of D6-25(OH)D3 — 360; 313; 263 milliliter per day (ml/d)
Phase 2 N=56 Cantharidin and Occlusion in Verruca Epithelium
Common Wart · Warts Hand · Warts
Primary: Cohort 1: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at the EOS Visit (Day 84) — 4 Participants
Phase 4 N=47 ED90 of 3% Chloroprocaine for Cervical Cerclage
Cerclage, Cervical
Primary: The Dose of Intrathecal (IT) Chloroprocaine That Provides Effective Anesthesia in 90% of Patients Undergoing Elective Cerclage Placement (Intraoperative Analgesic…
N/A N=27 Spinal Cord Stimulation in Patients With Post-Laminectomy Syndrome in Testing Phase
Laminectomy · Post-laminectomy Syndrome · Spinal Cord Syndrome
Primary: Comparing Visual Analogue Scale (VAS) — 9.3; 8.6; 5.7; 4.9 score on a scale — p=0.112
Phase 2 N=146 A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma
Uveal Melanoma
Primary: Number of Participants With a Dose Limiting Toxicity (DLT) in Phase 1 — 0; 1; 2; 0 Participants
Phase 2 N=15 A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD
Epilepsy · Tuberous Sclerosis Complex · Focal Cortical Dysplasia
Primary: Number of Patients With Adverse Events — 0; 0 Participants
N/A N=114 Comparative Effects of Moxonidine on Bone Metabolism, Vascular and Cellular Aging in Hypertensive Postmenopausal Women
Osteopenia · Arterial Hypertension
Primary: Collagen Type 1 C-telopeptide — 0.4; 0.4; 0.3; 0.4 ng/ml
Phase 1 N=43 Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
Bladder Cancer
Primary: Grade 3 or Higher Treatment Related Adverse Events as Assessed by CTCAE V5.0 — 0; 0.07 proportion of participants
Phase 2 N=76 Efficacy Study of Pharmacokinetic(PK)/Pharmacodynamic(PD) Relationship of Monotherapy MORAb-004 in Metastatic Melanoma
Metastatic Melanoma
Primary: Percentage of Participants With Progression-free Survival (PFS) at Week 24 — 13.5; 8.9 percentage of participants
N/A N=35 Evaluation of Visual Performance of Two Types of Cosmetic Contact Lenses
Visual Acuity
Primary: Distance Monocular Visual Acuity (logMAR) — -0.016; -0.001; -0.171; -0.151 logMAR